Anti-B7H3 tumor-targeted radioimmunotherapy has been studied using 124I- or 131I-omburtamab administered in the cerebrospinal fluid (CSF) [1], intraperitoneum [7] and intratumor cavity [8]. The gene discussed is CD276; the disease is neoplasm.